Shares of Novo Nordisk moved higher after the European Commission approved the company’s once-daily oral version of Wegovy for adults living with obesity or overweight conditions accompanied by at least one weight-related illness. The decision marks an important milestone for the Danish pharmaceutical company, making Wegovy the first oral GLP-1 therapy authorized for weight management across the European Union. The approval further intensifies competition in one of the fastest-growing segments of the global pharmaceutical industry.

European Approval Expands Novo Nordisk’s Market Reach

The latest authorization allows Novo Nordisk to market oral Wegovy across all European Union member states, adding another major regulatory victory following previous approvals in the United States, the United Kingdom, the United Arab Emirates and Bahrain. Regulators also approved a new single-dose pen for the higher 7.2-milligram injectable version of Wegovy, broadening treatment options for patients and healthcare providers.

The approval was supported by data from the OASIS clinical program, where patients receiving the oral therapy alongside lifestyle changes achieved significantly greater average weight loss than those receiving a placebo. The safety profile remained broadly consistent with the injectable version, reinforcing confidence in the treatment’s established clinical characteristics.

Oral Therapies Could Reshape the Obesity Market

The introduction of oral GLP-1 medications is widely viewed as the next major phase in obesity treatment. While injectable therapies have experienced extraordinary commercial success, many patients prefer oral medications because of their convenience and ease of administration. This shift could substantially expand the addressable market by attracting individuals who have been hesitant to begin injectable treatment.

Novo Nordisk has already experienced strong early demand following the U.S. launch of oral Wegovy, with millions of prescriptions generated during the first half of 2026. A significant portion of those prescriptions came from patients who had not previously used GLP-1 therapies, suggesting that oral formulations may broaden patient adoption rather than simply replace existing injectable treatments.

Competition With Eli Lilly Continues to Intensify

Despite Novo Nordisk’s latest regulatory success, competition remains fierce. Eli Lilly continues advancing its own oral obesity treatment through global regulatory reviews, including submissions in the European Union. The rivalry between the two pharmaceutical leaders is expected to remain one of the defining themes in the healthcare sector as demand for weight-management therapies continues growing worldwide.

Looking ahead, investors will monitor the pace of commercial launches across Europe, prescription growth, manufacturing capacity and additional regulatory approvals. While Novo Nordisk currently holds a first-mover advantage in Europe’s oral GLP-1 market, sustained leadership will depend on continued innovation, reliable product supply and expanding patient access. As the obesity treatment market evolves, the competition between Novo Nordisk and Eli Lilly is likely to remain a key driver of pharmaceutical industry growth and investor attention.